Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal healt… Read more
Alembic Pharmaceuticals Limited (APLLTD) - Total Assets
Latest total assets as of September 2025: ₹83.97 Billion INR
Based on the latest financial reports, Alembic Pharmaceuticals Limited (APLLTD) holds total assets worth ₹83.97 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alembic Pharmaceuticals Limited - Total Assets Trend (2011–2025)
This chart illustrates how Alembic Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Alembic Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Alembic Pharmaceuticals Limited's total assets of ₹83.97 Billion consist of 52.6% current assets and 47.4% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 1.2% |
| Accounts Receivable | ₹14.00 Billion | 18.0% |
| Inventory | ₹22.88 Billion | 29.4% |
| Property, Plant & Equipment | ₹33.61 Billion | 43.2% |
| Intangible Assets | ₹0.00 | 0.0% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Alembic Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alembic Pharmaceuticals Limited's current assets represent 52.6% of total assets in 2025, a decrease from 64.2% in 2011.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2025, up from 0.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 43.2% of total assets.
Alembic Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Alembic Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Alembic Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Alembic Pharmaceuticals Limited generates 0.86x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Alembic Pharmaceuticals Limited generates $7.51 in net profit.
Alembic Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 1.73 | 2.52 |
| Quick Ratio | 0.66 | 0.81 | 1.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹16.19 Billion | ₹ 15.91 Billion | ₹ 15.39 Billion |
Alembic Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Alembic Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 20.6% |
| Total Assets | ₹77.73 Billion |
| Market Capitalization | $452.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Alembic Pharmaceuticals Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Alembic Pharmaceuticals Limited's assets grew by 20.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alembic Pharmaceuticals Limited (2011–2025)
The table below shows the annual total assets of Alembic Pharmaceuticals Limited from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹77.73 Billion | +20.59% |
| 2024-03-31 | ₹64.46 Billion | +4.25% |
| 2023-03-31 | ₹61.83 Billion | -13.19% |
| 2022-03-31 | ₹71.22 Billion | +6.16% |
| 2021-03-31 | ₹67.09 Billion | +12.02% |
| 2020-03-31 | ₹59.89 Billion | +25.35% |
| 2019-03-31 | ₹47.78 Billion | +21.23% |
| 2018-03-31 | ₹39.41 Billion | +46.69% |
| 2017-03-31 | ₹26.87 Billion | +9.24% |
| 2016-03-31 | ₹24.59 Billion | +49.86% |
| 2015-03-31 | ₹16.41 Billion | +34.76% |
| 2014-03-31 | ₹12.18 Billion | +16.22% |
| 2013-03-31 | ₹10.48 Billion | -0.39% |
| 2012-03-31 | ₹10.52 Billion | +24.69% |
| 2011-03-31 | ₹8.44 Billion | -- |